Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.52 |
| ▸ | HPGD | P15428 | 2/20 | 0.50 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.50 |
| ▸ | HINT1 | P49773 | 1/20 | 0.48 |
| ▸ | NT5E | P21589 | 1/20 | 0.48 |
| ▸ | PNP | P00491 | 1/20 | 0.46 |
| ▸ | GSK3A | P49840 | 2/20 | 0.45 |
| ▸ | RPS6KA3 | P51812 | 2/20 | 0.45 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | STING1 | Q86WV6 | 2/20 | 0.45 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.45 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6537055 | 0.90 | ADORA3 (0.53) | ADORA3HPGDADORA2AHINT1NT5E | |
| 2'-B-Methyl-Guanosine SCHEMBL18537392 | 0.88 | ADORA2A (0.65) | ADORA3HPGDADORA2AHINT1NT5E | |
| 2'-B-Methyl-Guanosine SCHEMBL12758165 | 0.88 | ADORA2A (0.65) | ADORA3HPGDADORA2AHINT1NT5E | |
| SCHEMBL546453 | 0.88 | ADORA3 (0.51) | ADORA3HPGDADORA2AHINT1NT5E | |
| SCHEMBL15763440 | 0.88 | ADORA2A (0.54) | ADORA3HPGDADORA2AHINT1NT5E | |
| SCHEMBL14842252 | 0.88 | ADORA2A (0.52) | ADORA3HPGDADORA2AHINT1NT5E | |
| SCHEMBL13468483 | 0.88 | ADORA2A (0.54) | ADORA3HPGDADORA2AHINT1NT5E | |
| SCHEMBL21179099 | 0.88 | ADORA3 (0.51) | ADORA3HPGDADORA2AHINT1NT5E | |
| 2'-B-Methyl-Guanosine SCHEMBL21007207 | 0.88 | ADORA2A (0.65) | ADORA3HPGDADORA2AHINT1NT5E | |
| 2'-B-Methyl-Guanosine SCHEMBL14842089 | 0.88 | ADORA2A (0.65) | ADORA3HPGDADORA2AHINT1NT5E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 484 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025024123-A1 | NOVEL CITICOLINE DERIVATIVES | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2025-01-30 | — | — | WO | claimed |
| US-20240191231-A1 | SPINAL MUSCULAR ATROPHY (SMA) TREATMENT VIA TARGETING OF SMN2 SPLICE SITE INHIBITORY SEQUENCES | UNIV MASSACHUSETTS (US) | 2024-06-13 | — | — | US | claimed |
| WO-2023154964-A1 | METHODS AND COMPOSITIONS FOR TARGETING EFEMP1 | ALLOY THERAPEUTICS, INC. (US) | 2023-08-17 | — | — | WO | claimed |
| US-20220112494-A1 | IN VIVO GENE SILENCING BY CHEMICALLY MODIFIED AND STABLE siRNA | UNIVERSITY OF MASSACHUSETTS | 2022-04-14 | — | — | US | claimed |
| US-20220090071-A1 | SPINAL MUSCULAR ATROPHY (SMA) TREATMENT VIA TARGETING OF SMN2 SPLICE SITE INHIBITORY SEQUENCES | UNIV MASSACHUSETTS (US) | 2022-03-24 | — | — | US | claimed |
| US-11136578-B2 | In vivo gene silencing by chemically modified and stable siRNA | UNIVERSITY OF MASSACHUSETTS (US) | 2021-10-05 | — | — | US | claimed |
| US-11053503-B2 | Methods and means of generating IL-17 associated antitumor effector cells by inhibition of NR2F6 inhibition | KCL THERAPEUTICS, INC | 2021-07-06 | — | — | US | claimed |
| WO-2021117122-A1 | PROPHYLACTIC OR THERAPEUTIC AGENT FOR LYSOSOMAL ACID LIPASE DEFICIENCY SYNDROME | 株式会社リボルナバイオサイエンス | 2021-06-17 | — | — | WO | claimed |
| US-20190292540-A1 | SPINAL MUSCULAR ATROPHY (SMA) TREATMENT VIA TARGETING OF SMN2 SPLICE SITE INHIBITORY SEQUENCES | UNIV MASSACHUSETTS (US) | 2019-09-26 | — | — | US | claimed |
| US-10266822-B2 | Spinal muscular atrophy (SMA) treatment via targeting of SMN2 splice site inhibitory sequences | UNIVERSITY OF MASSACHUSETTS (US) | 2019-04-23 | — | — | US | claimed |
| US-20140155463-A1 | SPINAL MUSCULAR ATROPHY TREATMENT VIA TARGETING SMN2 CATALYTIC CORE | IOWA STATE UNIVERSITY RESEARCH FOUNDATION, INC. (US) | 2014-06-05 | — | — | US | claimed |
| WO-2013158046-A1 | RNAI-BASED THERAPIES FOR CARDIOMYOPATHIES, MUSCULAR DYSTROPHIES AND LAMINOPATHIES | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2013-10-24 | — | — | WO | claimed |
| US-20130174286-A1 | In Vivo Gene Silencing By Chemically Modified and Stable siRNA | UNIVERSITY OF MASSACHUSETTS (US) | 2013-07-04 | — | — | US | claimed |
| US-20120165394-A1 | SPINAL MUSCULAR ATROPHY (SMA) TREATMENT VIA TARGETING OF SMN2 SPLICE SITE INHIBITORY SEQUENCES | UNIVERSITY OF MASSACHUSETTS (US) | 2012-06-28 | — | — | US | claimed |
| US-8110560-B2 | Spinal muscular atrophy (SMA) treatment via targeting of SMN2 splice site inhibitory sequences | UNIVERSITY OF MASSACHUSETTS (US) | 2012-02-07 | — | — | US | claimed |
| US-20110269820-A1 | SPINAL MUSCULAR ATROPHY TREATMENT VIA TARGETING SMN2 CATALYTIC CORE | IOWA STATE UNIVERSITY RESEARCH FOUNDATION, INC. (US) | 2011-11-03 | — | — | US | claimed |
| US-7838657-B2 | compositions capable of blocking the inhibitory effect of a newly-identified intronic inhibitory sequence element, named ISS-N1 (intronic splicing silencer), located in the SMN2 gene | UNIVERSITY OF MASSACHUSETTS (US) | 2010-11-23 | — | — | US | claimed |
| US-20100087511-A1 | SPINAL MUSCULAR ATROPHY (SMA) TREATMENT VIA TARGETING OF SMN2 SPLICE SITE INHIBITORY SEQUENCES | UNIVERSITY OF MASSACHUSETTS (US) | 2010-04-08 | — | — | US | claimed |
| US-20070292408-A1 | Spinal Muscular Atrophy (SMA) treatment via targeting of SMN2 splice site inhibitory sequences | UNIVERSITY OF MASSACHUSETTS (US) | 2007-12-20 | — | — | US | claimed |
| US-20050020521-A1 | Rna interference strands and antibody strands | UNIVERSITY OF MASSACHUSETTS (US) | 2005-01-27 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110269820-A1 | SPINAL MUSCULAR ATROPHY TREATMENT VIA TARGETING SMN2 CATALYTIC CORE | SMN1; SMN2, MSI2, RBM17 | ADORA3 3605/4885HPGD 4534/4885ADORA2A 3229/4885 |
| US-20220112494-A1 | IN VIVO GENE SILENCING BY CHEMICALLY MODIFIED AND STABLE siRNA | SNRPE, AGO2, NSUN2 | ADORA3 2303/4885HPGD 4405/4885ADORA2A 2178/4885 |
| US-20050020521-A1 | Rna interference strands and antibody strands | AGO2, NSUN3, NSUN2 | ADORA3 1516/4885HPGD 4828/4885ADORA2A 1935/4885 |
| US-11136578-B2 | In vivo gene silencing by chemically modified and stable siRNA | SNRPE, AGO2, NSUN2 | ADORA3 2303/4885HPGD 4405/4885ADORA2A 2178/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.